

December 20, 2020

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Sub: AstraZeneca Pharma India Limited receives Import and Market Permission in Form CT-20 (Marketing Authorization) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra™)

This is to inform that AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (**Marketing Authorization**) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra™).

Benralizumab (Fasenra™) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

The receipt of this permission paves way for the launch of Benralizumab (Fasenra™) in India, subject to the receipt of related statutory approvals and licenses.

We request you to kindly take the same on record.

For **AstraZeneca Pharma India Limited**

Pratap Rudra

Company Secretary & Legal Counsel